Catalysts for Janssen Biotech Inc

LAZCLUZE (LAZERTINIB MESYLATE) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

SIMPONI (GOLIMUMAB) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

LAZCLUZE (LAZERTINIB MESYLATE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval